A Nano-Imprinted Plastic Laser

<p>Prevalence of a) insulin and b) oral antidiabetic medicine prescribing in women with a delivery, between 2004 and 2010, during each of the 3-month time periods.</p

Percentage of deliveries where the woman received a prescription for insulin or an antidiabetic medicine in the year before pregnancy, during pregnancy or the year following pregnancy.

<p>Percentage of deliveries where the woman received a prescription for insulin or an antidiabetic medicine in the year before pregnancy, during pregnancy or the year following pregnancy.</p

Breakdown of the type of analogue insulin prescribed during each of the time periods in each region.

<p>Breakdown of the type of analogue insulin prescribed during each of the time periods in each region.</p

Percentage of pregnancies where the woman received her first prescription for an antidiabetic medicine during the second or third trimester of pregnancy (as an indication of pharmacologically treated gestational diabetes) by region and calendar year.

<p>Percentage of pregnancies where the woman received her first prescription for an antidiabetic medicine during the second or third trimester of pregnancy (as an indication of pharmacologically treated gestational diabetes) by region and calendar year.</p

Trends in the prescribing of insulins during pregnancy by region and calendar year.

<p>Trends in the prescribing of insulins during pregnancy by region and calendar year.</p

Trends in the prescribing of antidiabetic medicines during the first trimester of pregnancy by region and calendar year.

<p>Trends in the prescribing of antidiabetic medicines during the first trimester of pregnancy by region and calendar year.</p

Prevalence of anomalies from 2003 to 2012, the annual proportional change during this period and the adjusted annual proportional change after excluding outliers for the 17 anomaly subgroups with statistically significant trends identified in Fig 1.

<p>Prevalence of anomalies from 2003 to 2012, the annual proportional change during this period and the adjusted annual proportional change after excluding outliers for the 17 anomaly subgroups with statistically significant trends identified in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0194986#pone.0194986.g001" target="_blank">Fig 1</a>.</p

Prevalence and annual average change in prevalence for microcephaly and severe congenital heart disease.

<p>[A] European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend excluding outliers (red line) [B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI) [C] Annual change in prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend black dots, non-linear trend open diamonds). Red line is no trend. Severe CHD includes single ventricle, hypoplastic left heart, hypoplastic right heart, Ebstein anomaly, tricuspid atresia, pulmonary valve atresia, common arterial truncus, atrioventricular septal defects, aortic valve atresia/stenosis, transposition of great vessels, tetralogy of Fallot, total anomalous pulmonary venous return, and coarctation of aorta.</p

Prevalence and annual average change in prevalence for duodenal atresia or stenosis and ano-rectal atresia and stenosis.

<p>[A] European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend excluding outliers (red line) [B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI) [C] Annual change in prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend black dots, non-linear trend open diamonds). Red line is no trend.</p

Prevalence and annual average change in prevalence for congenital cystic adenomatous malformation of lung and oesophageal atresia.

<p>[A] European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend excluding outliers (red line) [B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI) [C] Annual change in prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend black dots, non-linear trend open diamonds). Red line is no trend.</p